Stocks / XYL

Xylem Inc.'s 10-K, read.

Bob rates Xylem Inc. (XYL) 62/100, lean bullish, on the 10-K filed February 25, 2026, updated through the 10-Q filed October 27, 2026.

62
Bearish 0Lean bearish 32Neutral 45Lean bullish 58Bullish 70
The Meter — latest SEC filing
XYLLean bullish
62/ 100

Xylem is a leading global water technology company with $9.0B in 2025 revenues and a $800B total addressable market, benefiting from secular growth drivers around water scarcity, quality, and infrastructure resilience. However, near-term headwinds—including organic revenue declines in key segments (Measurement & Control Solutions down 5.1% organically in Q3 2026), supply chain complexity, geopolitical tariff uncertainty, and exposure to emerging market softness—are offsetting margin gains from pricing and productivity, warranting a cautious stance despite improving profitability metrics.

  • Organic revenue declining: Q3 2026 shows -0.3% organic growth overall, with Measurement & Control Solutions down 5.1% organically and U.S. metering weakness noted as primary driver
  • Tariff and geopolitical exposure: U.S. Supreme Court affirmed tariff authority uncertainty in Feb 2026; company relies heavily on suppliers in China, Mexico, Taiwan for semiconductors and components
  • Supply chain concentration: Significant reliance on sole- and single-source suppliers for key components (PCBs, semiconductors, rare earth minerals); China-Taiwan tensions pose material disruption risk
  • Measurement & Control Solutions segment struggling: Revenue down 6.4% YTD 2026, with divestitures of $97M and organic declines of $23M; international metering divested in 2026
  • Backlog only 20% expected to convert to 2H 2026 revenue, suggesting demand timing uncertainty and potential for Q4 disappointment

Not investment advice — general research, the same for every reader. You make your own calls.

Want the full read?

Run XYL in Bob for the live meter, or go deep with five years of filings behind it.

Read XYL in Bob →

Last read October 28, 2026. Bob's Research is a financial publisher, not an investment adviser. Everything here is general research and education — not personalized advice, and not a recommendation to buy or sell any security. Ratings are the same for every reader. You make your own calls.